Essential thrombocythemia (ET) is a hematological malignancy characterized by thrombocytosis. Patients are classified into different categories and, as such, receive different therapies and prognoses based on their age and clinical findings. Although most patients respond adequately to first-line treatments, a high unmet need exists for second-line agents that can be used in patients who do not respond to or cannot tolerate first-line therapy.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States
Key drugs: Aspirin, hydroxyurea, peg-IFN, anagrelide, ruxolitinib